Research Interests
Research Interests
Dr. Green’s Biomaterials and Drug Delivery Laboratory is interested in biomaterials, drug delivery, gene therapy, nanobiotechnology, and cell engineering. Research findings — and the technologies developed — are applied in the fields of ophthalmology, oncology, and regenerative medicine.
The lab works within the chemistry/biology/engineering interface to answer fundamental scientific questions, and to create innovative technologies and therapeutics that can directly benefit human health.
Current projects include:
- Development of safe and effective biodegradable nanoparticles for DNA and siRNA delivery to treat cancer
- Polymeric microparticle-based biological treatments for age-related macular degeneration
- Design of biomimetic artificial antigen presenting cells for immunoengineering
- Enabling technologies for tissue engineering and regenerative medicine
Titles & Affiliations
Titles
- Herschel L. Seder Professor, Biomedical Engineering
- Vice Chair for Research and Translation, Department of Biomedical Engineering
- Professor, Ophthalmology
- Professor, Oncology
- Professor, Neurosurgery
- Professor, Materials Science & Engineering
- Professor, Chemical & Biomolecular Engineering
Affiliated Centers & Institutes
Education
Education
- PhD, Biological Engineering, Massachusetts Institute of Technology, 2007
- BS, Chemical Engineering, Biomedical Engineering, Carnegie Mellon University, 2003
Faculty News
Recent Highlights
-
December 18, 2024Through tailored training and engagement opportunities, fellows will become skilled in providing expert media commentary, proficient at adapting their message to various audiences and stakeholders, able to identify emerging topics of broad interest, and equipped to craft compelling narratives.
-
April 15, 2024Jordan Green, professor of biomedical engineering, was named the Herschel L. Seder Professor in biomedical engineering during an installation ceremony on April 9, 2024 at the Homewood Campus.
-
July 17, 2023A Johns Hopkins Medicine team suggests that microparticle-delivered therapy may be the first step toward stopping MS and other autoimmune diseases.
Media